JP2022502432A5 - - Google Patents

Info

Publication number
JP2022502432A5
JP2022502432A5 JP2021517294A JP2021517294A JP2022502432A5 JP 2022502432 A5 JP2022502432 A5 JP 2022502432A5 JP 2021517294 A JP2021517294 A JP 2021517294A JP 2021517294 A JP2021517294 A JP 2021517294A JP 2022502432 A5 JP2022502432 A5 JP 2022502432A5
Authority
JP
Japan
Prior art keywords
formulation
approximately
glp
analog
buffer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021517294A
Other languages
English (en)
Japanese (ja)
Other versions
JP7566730B2 (ja
JP2022502432A (ja
Filing date
Publication date
Priority claimed from EP18197755.4A external-priority patent/EP3628683A1/en
Application filed filed Critical
Publication of JP2022502432A publication Critical patent/JP2022502432A/ja
Publication of JP2022502432A5 publication Critical patent/JP2022502432A5/ja
Priority to JP2024120747A priority Critical patent/JP7738136B2/ja
Application granted granted Critical
Publication of JP7566730B2 publication Critical patent/JP7566730B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021517294A 2018-09-28 2019-09-27 グルカゴン様ペプチド-2(glp-2)類似体の製剤 Active JP7566730B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024120747A JP7738136B2 (ja) 2018-09-28 2024-07-26 グルカゴン様ペプチド-2(glp-2)類似体の製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18197755.4A EP3628683A1 (en) 2018-09-28 2018-09-28 Formulations of glucagon-like-peptide-2 (glp-2) analogues
EP18197755.4 2018-09-28
PCT/EP2019/076305 WO2020065064A1 (en) 2018-09-28 2019-09-27 Formulations of glucagon-like-peptide-2 (glp-2) analogues

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024120747A Division JP7738136B2 (ja) 2018-09-28 2024-07-26 グルカゴン様ペプチド-2(glp-2)類似体の製剤

Publications (3)

Publication Number Publication Date
JP2022502432A JP2022502432A (ja) 2022-01-11
JP2022502432A5 true JP2022502432A5 (cg-RX-API-DMAC7.html) 2022-09-13
JP7566730B2 JP7566730B2 (ja) 2024-10-15

Family

ID=63794308

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021517294A Active JP7566730B2 (ja) 2018-09-28 2019-09-27 グルカゴン様ペプチド-2(glp-2)類似体の製剤
JP2024120747A Active JP7738136B2 (ja) 2018-09-28 2024-07-26 グルカゴン様ペプチド-2(glp-2)類似体の製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024120747A Active JP7738136B2 (ja) 2018-09-28 2024-07-26 グルカゴン様ペプチド-2(glp-2)類似体の製剤

Country Status (13)

Country Link
US (2) US20220265551A1 (cg-RX-API-DMAC7.html)
EP (2) EP3628683A1 (cg-RX-API-DMAC7.html)
JP (2) JP7566730B2 (cg-RX-API-DMAC7.html)
KR (2) KR20260008798A (cg-RX-API-DMAC7.html)
CN (3) CN118267455A (cg-RX-API-DMAC7.html)
AU (1) AU2019348538B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021005858A2 (cg-RX-API-DMAC7.html)
CA (1) CA3114330A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021000678A1 (cg-RX-API-DMAC7.html)
IL (1) IL281362B2 (cg-RX-API-DMAC7.html)
MX (2) MX2021003271A (cg-RX-API-DMAC7.html)
SG (1) SG11202102383VA (cg-RX-API-DMAC7.html)
WO (1) WO2020065064A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL271245B2 (en) 2017-06-16 2023-10-01 Zealand Pharma As Dosing regimen for administration of glucagon-like peptide analog (GLP-2) 2
IL298298A (en) * 2020-05-22 2023-01-01 Hanmi Pharm Ind Co Ltd A liquid formulation of a long-acting conjugate of glp–2
MX2023006901A (es) * 2020-12-16 2023-06-26 Zealand Pharma As Uso de analogos de glp-2 en pacientes con insuficiencia renal.
WO2023036862A1 (en) * 2021-09-10 2023-03-16 Zealand Pharma A/S Process for formulating compositions comprising glucagon-like-peptide-2 (glp-2) analogues
WO2023118416A1 (en) 2021-12-23 2023-06-29 Zealand Pharma A/S Processes for synthesizing glucagon-like-peptide 2 (glp-2) analogues
KR20250075601A (ko) 2022-09-30 2025-05-28 질랜드 파마 에이/에스 글루카곤-유사-펩타이드-2(glp-2) 유사체 및 단장 증후군(sbs) 치료를 위한 이의 의학적 용도
WO2024075135A1 (en) * 2022-10-03 2024-04-11 Orbicular Pharmaceutical Technologies Private Limited "stable injectable compositions of glp-2 peptide"
TW202436330A (zh) 2023-01-27 2024-09-16 丹麥商西蘭製藥公司 類升糖素胜肽-2(glp-2)類似物及其用於治療短腸症候群(sbs)之醫藥用途
WO2025141129A1 (en) 2023-12-28 2025-07-03 Zealand Pharma A/S Formulations of glucagon-like-peptide 2 (glp-2) analogues and their uses

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ250844A (en) * 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition
US5789379A (en) 1995-04-14 1998-08-04 Allelix Biopharmaceutical Inc. Glucagon-like peptide-2 analogs
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
EP2275438A1 (en) 1996-04-12 2011-01-19 1149336 Ontario Inc. Glucagon-like peptide-2 analogs
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
WO2001041779A2 (en) 1999-12-08 2001-06-14 1149336 Ontario Inc. Combined use of glp-2 receptor agonist and chemotherapeutic agent in treatment
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
DK1360202T3 (da) 2001-02-16 2008-09-22 Conjuchem Biotechnologies Inc Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser
EP2119724A1 (en) * 2005-05-03 2009-11-18 Novetide Ltd. Solid-phase process foor the preparation of goserelin
DE602006020123D1 (de) * 2005-05-04 2011-03-31 Zealand Pharma As Glucagon-like-peptide-2- (glp-2-) analoga
CN101341254A (zh) * 2005-12-24 2009-01-07 蒂加斯克乳制品研究中心 反-10,顺-12十八碳二烯酸的生产方法
US20090028832A1 (en) * 2006-08-10 2009-01-29 Chung Leland F Compositions and methods for targeted tumor therapy
AU2007319066B2 (en) * 2006-11-08 2013-09-19 Zealand Pharma A/S Selective glucagon-like-peptide-2 (GLP-2) analogues
CN101668535B (zh) * 2006-12-29 2017-07-28 益普生制药股份有限公司 Glp‑1药物组合物
JP2013533217A (ja) * 2010-05-17 2013-08-22 セビックス・インコーポレイテッド Peg化c−ペプチド
FR2994390B1 (fr) * 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
US9636407B2 (en) * 2012-11-20 2017-05-02 Fresenius Kabi Usa, Llc Caspofungin acetate formulations
ES2964713T3 (es) * 2014-10-23 2024-04-09 Amgen Inc Reducción de la viscosidad de formulaciones farmacéuticas
SMT202500120T1 (it) * 2016-11-21 2025-05-12 Amylyx Pharmaceuticals Inc Formulazioni tamponate di esendina (9-39)

Similar Documents

Publication Publication Date Title
ES2320754T3 (es) Tratamiento de la diabetes.
US10383918B2 (en) Compositions in the form of an injectable aqueous solution comprising human glucagon and a statistical co-polyamino acid
ES2365410T3 (es) Formulaciones farmacéuticas que comprenden péptido de incretina y un disolvente polar aprótico.
JP6111475B2 (ja) ヒトインスリン又はその類似体もしくは誘導体を含む安定な水性組成物
MD3810201T2 (ro) Compoziții agonişte GIP/GLP1
HK1248607A1 (zh) Ph为7且至少含pi为5.8至8.5之基础胰岛素和取代共聚(氨基酸)的可注射溶液
AU2019348538B2 (en) Formulations of glucagon-like-peptide-2 (GLP-2) analogues
JP7847615B2 (ja) 1日ごとのソマトロピンよりも優れた効力を有する長時間作用性成長ホルモン剤形
TW201938189A (zh) 包含至少一具有pi從5.8至8.5之基礎胰島素以及一帶有羧酸鹽電荷及疏水基之共聚胺基酸的可注射ph7溶液
CN110087666B (zh) 用于治疗糖尿病、高血压和高胆固醇血症的组合物和方法
JP2008521840A5 (cg-RX-API-DMAC7.html)
WO2009068708A2 (es) Composición farmacéutica de liberación sostenida de somatostatina o un análogo suyo
CN107661288A (zh) 含有glp‑1 类似物融合蛋白的稳定液体制剂及其制备
EP3856767B1 (en) Formulations of glucagon-like-peptide-2 (glp-2) analogues
JP2021519321A5 (cg-RX-API-DMAC7.html)
EP2604264B1 (en) Pharmaceutical composition for treating viral diseases
US11963940B2 (en) Parenteral esmolol formulation
TW201815410A (zh) 藥物之經黏膜吸收促進劑
RU2021106892A (ru) Составы аналогов глюкагоноподобного пептида-2 (glp-2)
RS67423B1 (sr) Postupak za formulisanje sastava koji sadrže analoge glukagonu sličnog peptida-2 (glp-2)
WO2022173006A1 (ja) 難吸収性薬物の吸収性が改善された組成物
JP3022915B2 (ja) 癌転移抑制剤
CN108025042A (zh) PTHrP类似物的新型制剂
RU2833459C2 (ru) Составы аналогов глюкагоноподобного пептида-2 (glp-2)
CA3041362C (en) Compositions and methods for treating diabetes, hypertension and hypercholesterolemia